Lilly and Rigel have agreed to a $960 million RIPK1 inhibitor partnership

On Thursday, Lilly announced an exclusive licensing agreement with Rigel Pharmaceuticals, in which the two companies will jointly develop Rigel's RIPK1 inhibitor R552 and will be responsible for the commercialization of the therapy for all adaptations, including autoimmune and inflammatory diseases.
as part of the deal, Lilly will obtain a global exclusive license for the recombinant protein 1 recombinant protein (RIPK1) inhibitor R552, which interacts with the subject.
RIPK1 is a key signaling protein that scientific tests have confirmed can cause a wide range of inflammatory cellular processes by causing cell rupture.
R552 is an oral RIPK1 inhibitor once a day after the therapy was tested for Phase I safety in healthy people.
preclinical studies, R552 has been shown to prevent joint and skin inflammation in mice.
the partnership, the two companies plan to begin a Phase II TRIAL of RIPK1 inhibitors this year, which currently includes known adaptive diseases, including autoimmune and inflammatory diseases.
addition to Lilly's $125 million upfront payment to Rigel, Rigel will also be eligible for a milestone payment of $835 million, as well as tiered royalties.
addition, Rigel will be eligible to work with Lilly on the commercialization of R552 in the United States, while Lilly will bear the global commercialization costs of R552.
Rigel has other RIPK1 inhibitors that penetrate the brain barrier in its preclinical product line, which Lilly may use in future clinical studies of neurological disorders.
said Lilly's move was also aimed at competing with Sanofi, which is also involved in the RIPK1 inhibitor space.
as early as 2018, Sanofi has been working with Denali Therapeutics, a biopharmaceutical company focused on the development of drugs for neurodegenerative diseases, to develop a variety of RIPK1 inhibitor molecules for the treatment of a range of neurological and systemic inflammatory diseases, including multiple sclerosis, Alzheimer's disease and amyotrophic lateral sclerosis, as well as systemic inflammatory diseases such as rheumatoid arthritis and psoriasis), the main co-products are DNL747 and DNL758.
noted that the two companies launched phase II DNL758 trials in lupus earlier this year.
addition to this, a $960 million RIPK1 inhibitor partnership with Rigel will help Lilly further deepen its neurology and immunology portfolio.
December, Lilly and Prevail Therapeutics, which is working to develop gene therapy based on adenopathic virus 9 (AAV9) vectors for patients with neurodegenerative diseases, reached a $1.04 billion acquisition agreement.
acquisition will build a gene therapy development program within Lilly based on Prevail's research and development pipeline to broaden the treatment model for inherited neurodegenerative diseases.
total revenue for the full year was $24.54 billion, up 10 percent from a year earlier and higher than Lilly's revenue forecast of $23.7 billion to $24.2 billion at the start of the year, according to Lilly's 2020 financial results.
Lilly also disclosed full-year sales revenue for China in its annual report for the first time, reaching $1.117 billion.
addition, Lilly is accelerating the distribution of cutting-edge innovative therapies beyond traditional drugs, and currently has at least eight drug candidates in clinical development for neurodegenerative diseases, including donanemab.
But Lilly's shares did not appear to have been affected by the good news, falling 1.21 per cent to $203.96 by Thursday's close, while Rigel's rose 14.79 per cent to $5.20.
: 1.Lilly, Rigel to Partner on RIPK1 Addors in Deal Worth Up to $960 Million Deal Deal With Rigel In Push Neurological, Immunological Therapies 3.Lilly, Rigel Exclusive Exclusive CN Shine Development Development 4.Rigels with Lilly deal $960